Phase 3 study of CPN-302: Positive topline results for post-cataract surgery drug candidate
August 13th 2022The companies note that data from Study CPN-302 confirm the results in the first Phase 3 study, CPN-301, and they demonstrate the clear benefits of treating patients after cataract surgery with APP13007.
Enrolment begins in Phase 2 study for therapeutic for persistent corneal epithelial defects
July 10th 2022Kiora Pharmaceuticals announced it has enrolled the first patient as a part of a Phase 2 study evaluating KIO-201 topical eye drops in patients with PCED, a rare ocular surface condition characterized by non-healing wounds on the eye surface.
Intraventricular haemorrhage in first year may lead to long-term sight problems
July 9th 2022Researchers at the University of Bristol, as part of a 10-year follow-up study, found that severe “brain bleeds” experienced by some babies in the first year following their birth lead to long-term sight problems.
Self-plugging microneedles may improve drug delivery in the eye
June 27th 2022In a recent study, investigators found preclinical evidence that this innovative, biodegradable microneedle, dip-coated with a therapeutic drug for release upon insertion into the eyeball, can also be equipped with a special hydrogel that simultaneously seals off the insertion hole.
Link discovered between eye health, diet and lifespan
June 21st 2022According to investigators, a key reason for the link may lie in circadian “clocks,” the molecular machinery within every cell of every organism, which have evolved to adapt to daily stresses, such as changes in light and temperature caused by the rising and setting of the sun.
Brolucizumab-dbll 6 mg approved by US FDA for treatment of diabetic macular oedema
June 2nd 2022According to Novartis, the approval is based on year 1 data from the Phase III KESTREL and KITE clinical trials investigating brolucizumab-dbll 6 mg vs aflibercept 2 mg in diabetic macular oedema patients.